Oncodesign Precision Medicine
Manufacturing · France · 11-50 Employees
View Company Info for Free
Overview
Headquarters
18 Rue Jean Mazen, Dijon, Bourgogne-Fran...Phone Number
+33 380788260Website
www.oncodesign.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
2
1
1
1
1
About Oncodesign Precision Medicine
Oncodesign Precision Medicine, founded in 1995 and headquartered in Dijon, France, is a biopharmaceutical company specializing in research and development of therapeutic and diagnostic tools. The company provides integrated drug discovery services including in vitro and in vivo pharmacology, metabolism studies, and pharmacokinetics of drug candidates. Oncodesign offers translational biomarker services, biodecontamination, biosafety, and biobanking capabilities. The company focuses on kinase inhibitor development programs in oncology, central nervous system disorders, and inflammation. Oncodesign maintains strategic partnerships for advancing oncology treatments and collaborates on fibrosis drug candidate development. As a pharmaceutical manufacturer, the company combines scientific expertise with technological innovation to develop precision medicine solutions.Explore more
Oncodesign Precision Medicine Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Oncodesign Precision Medicine your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Oncodesign Precision Medicine, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Oncodesign Precision Medicine recently announced quarterly report
Click to see if Oncodesign Precision Medicine had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Oncodesign Precision Medicine has new funding data
Product Launch: Get notified when Oncodesign Precision Medicine launches new products
Check out if Oncodesign Precision Medicine is spiking on competitors!
Website visits: Recent activity has been detected on your website
Check if Oncodesign Precision Medicine has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Oncodesign Precision Medicine
Recommended Actions
Find VP level buyers at Oncodesign Precision Medicine
Find 2 more new buyers
Company Profile Activity
Activity Insights
Oncodesign Precision Medicine is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Oncodesign Precision Medicine is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Oncodesign Precision Medicine.
Oncodesign Precision Medicine financials insights
Gather financial insights about Oncodesign Precision Medicine, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2023
Other Financing Round
$6.3M
Oncodesign Precision Medicine Tech Stack
A closer look at the technologies used by Oncodesign Precision Medicine
See more technologies
Most Recent Scoops
Person-Based
Person-Based
Mergers & Acquisitions (M&A)
Funding
Oncodesign Precision Medicine News & Media
Oncodesign Precision Medicine Reacquires Rights to Its OPM-201 Program From Servier After a Positive Phase I Trial in Healthy Volunteers
DIJON, France--(BUSINESS WIRE)--Regulatory News: Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, today announces the reacquisition of the rights to its OPM-201 program in the treatment of Parkinson’s disease from Servier laboratories. The Phase I healthy volunteer study, initiated in October 2022, has just been completed, confirming the safety of OPM-2Oncodesign Precision Medicine (OPM) obtains €5.6 million in public funding for its DEMOCRITE program dedicated to the clinical development of OPM-101
DIJON, France--(BUSINESS WIRE)--Regulatory News: Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancer, announced today that it has received notice of the grant of funding associated with the "i-Démo n°2" call for projects as part of the France 2030 plan. The aim of this call for projects is to develop industrial and service companies in growth markets that crOncodesign Precision Medicine Obtains Deep Tech Development Funding for Its ANIMUS Program
DIJON, France--(BUSINESS WIRE)--Regulatory News: Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63 ; Mnemonic : ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancer, announces today that it has received notification of the allocation of financial support from the Deep Tech Development Fund. The funding is granted through a combination of grants and a repayable advance to finance R&D investment. This support is finaOncodesign Precision Medicine receives ERDF fund totalling €2.1 M for its COMETE program
DIJON, France--(BUSINESS WIRE)--Regulatory News: Oncodesign Precision Medicine (OPM) (ISIN : FR001400CM63 ; Mnemonic : ALOPM) (Paris:ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancer, is pleased to announce that it has receive notification of the allocation of financial support from the European Regional Development Fund (ERDF) under the FEDER-SSE+ program for Bourgogne Franche-Comté and Massif du Jura 2021-2027 program (
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Oncodesign Precision Medicine
Sign Up For FreeTo access detailed company insights
Oncodesign Precision Medicine, founded in 1995 and headquartered in Dijon, France, is a biopharmaceutical company specializing in research and development of therapeutic and diagnostic tools. The company provides integrated drug discovery services including in vitro and in vivo pharmacology, metabolism studies, and pharmacokinetics of drug candidat... Read More
